Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test [In the Spotlight]

Summary: Comprehensive plasma DNA analysis identifies clinically actionable genomic aberrations. Cancers harboring disruption of TP53 or BRCA2 or ATM detected in plasma have significantly worse outcomes on novel AR targeting. Cancer Discov; 8(4); 392–4. ©2018 AACR.

See related article by Annala et al., p. 444.

from Cancer via ola Kala on Inoreader https://ift.tt/2GqBVR5
via IFTTT